Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi ...

Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...

The Simponi recall stemmed from a manufacturing problem in Switzerland. As Dow Jones reports, many of the affected lots were set aside before hitting the market, but some 395 of the prefilled ...

NEW YORK, Feb 18 (Reuters) - Johnson & Johnson said it has recalled two lots of Simponi injection devices -- one in the United States and one in Europe -- after discovering they may deliver less than ...

SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...